Trial Profile

A Phase 1/2, Open-Label, Multicenter, Dose-Finding Study of SKL27969 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy in Patients With Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 14 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SKL 27969 (Primary)
Indications Advanced breast cancer; Glioma; Non-small cell lung cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Sponsors SK Life Science

31 Mar 2024 Status changed from active, no longer recruiting to discontinued for portfolio prioritization. No safety trends or issues were identified at any dose level.
01 Feb 2024 Status changed from recruiting to active, no longer recruiting.
25 Jul 2022 Planned initiation date changed from 1 Jun 2022 to 25 Jul 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com